insights_auto
Kāpēc uzņēmuma JAZZ akciju cena ir samazinājusies 2,93%?
Atklājiet vairāk iespējuchevron_right
JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
210,39 $
arrow_downward
-2,93%(-6,36) 1 d.
210,39 $
0,00% (0,00)
bedtimePēctirdzniecības
Slēgts: 13. okt., 16:00:01 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: JAZZ…
Atvērt
216,86 $
Augsta
216,86 $
Zema
209,34 $
Tirgus kapitalizācija
13,66 mljrd.
Vid. apjoms
805,39 tūkst.
Apjoms
812,64 tūkst.
Cenas/peļņas attiecība
14,39
Augstākā 52 ned.
266,38 $
Zemākā 52 ned.
128,80 $
Peļņa uz vienu akciju
14,63 $
Beta
0,37
Apgrozībā esošās akcijas
64,92 milj.
Darbinieku skaits
3 tūkst.
Atvērt
216,86 $
Augsta
216,86 $
Zema
209,34 $
Tirgus kapitalizācija
13,66 mljrd.
Vid. apjoms
805,39 tūkst.
Apjoms
812,64 tūkst.
Cenas/peļņas attiecība
14,39
Augstākā 52 ned.
266,38 $
Zemākā 52 ned.
128,80 $
Peļņa uz vienu akciju
14,63 $
Beta
0,37
Apgrozībā esošās akcijas
64,92 milj.
Darbinieku skaits
3 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Benzinga
·
pirms 1 dienas
Jim Cramer Gives Green Light To This Health Care Stock
Investing.com India
·
pirms 3 dienām
Form 144 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY For: 10 October
Profils
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Par “Jazz Pharmaceuticals PLC”
ĢenerāldirektorsBruce C Cozadd
Darbinieki2,89 tūkst.
Dibināšanas datums2003
Galvenais birojs-
Sektors-
Tīmekļa vietnejazzpharma.com